Institutional shares held 18.1 Million
26.8K calls
9.3K puts
Total value of holdings $2.08B
$3.07M calls
$1.07M puts
Market Cap $1.92B
16,882,800 Shares Out.
Institutional ownership 107.3%
# of Institutions 256


Latest Institutional Activity in LGND

Top Purchases

Q3 2024
Granite Investment Partners, LLC Shares Held: 118K ($13.4M)
Q3 2024
Loomis Sayles & CO L P Shares Held: 373K ($42.4M)
Q3 2024
Penn Capital Management Company, LLC Shares Held: 100K ($11.4M)
Q3 2024
Driehaus Capital Management LLC Shares Held: 95.7K ($10.9M)
Q3 2024
Cibc World Market Inc. Shares Held: 84.1K ($9.57M)

Top Sells

Q3 2024
Macquarie Group LTD Shares Held: 887K ($101M)
Q3 2024
Stephens Investment Management Group LLC Shares Held: 619K ($70.4M)
Q3 2024
Ubs Group Ag Shares Held: 11.5K ($1.31M)
Q3 2024
Citadel Advisors LLC Shares Held: 23.8K ($2.71M)
Q3 2024
Sei Investments CO Shares Held: 26.8K ($3.05M)

About LGND

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.


Insider Transactions at LGND

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
148K Shares
From 24 Insiders
Grant, award, or other acquisition 70K shares
Other acquisition or disposition 1.48K shares
Exercise of conversion of derivative security 74K shares
Open market or private purchase 2.5K shares
Sell / Disposition
120K Shares
From 10 Insiders
Payment of exercise price or tax liability 16.2K shares
Open market or private sale 104K shares

Track Institutional and Insider Activities on LGND

Follow LIGAND PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LGND shares.

Notify only if

Insider Trading

Get notified when an Ligand Pharmaceuticals Inc insider buys or sells LGND shares.

Notify only if

News

Receive news related to LIGAND PHARMACEUTICALS INC

Track Activities on LGND